

| Country Demographics ^{1,2,3} | |
|---|-----------|
| Total population (2017) ¹ | 4,705,818 |
| Urban population (% of total, 2016) ¹ | 86% |
| Health expenditure per capita (\$US, 2016) ² | \$3,745.2 |
| Health expenditure, total (% of GDP, 2016) ² | 9.2% |
| Total births (2017) ¹ | 61,807 |
| Surviving infants (2017) ¹ | 61,568 |
| Life expectancy at birth (years, 2017) ² | 81.7 yrs |
| Number of districts (2013) ³ | 20 |


| HBsAg Prevalence ⁶ | |
|-------------------------------|-----|
| Pre-vaccine HBsAg+ (%) | <1% |

| Liver Cancer as Cause of Cancer Death (in Men) ⁵ | |
|---|------------|
| Year: 2018 | Ranking: 6 |

| 2018 Country Comparison in Western Pacific Region (37 Member States/Areas) ⁴ | | | | |
|---|-------------|--|--|---|
| | New Zealand | Number of member states with WHO-UNICEF estimated coverage | Highest WHO-UNICEF estimated coverage in WPR | Lowest WHO-UNICEF estimated coverage in WPR |
| HepB3 ⁴ | 93% | 26 | 99% (Brunei Darussalam, China, Cook Islands, Fiji, Malaysia, Mongolia, Niue) | 34% (Samoa) |
| HepB BD ⁴ | NR | 24 | 99% (Brunei Darussalam, Cook Islands, Palau, Tuvalu) | 25% (Papua New Guinea) |

| Hepatitis B Immunization Coverage ⁴ | | | | | | | | | | | | | | | | | | | |
|--|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
| HepB3 ⁴ | 90% | 90% | 89% | 89% | 88% | 87% | 87% | 88% | 90% | 93% | 90% | 95% | 93% | 93% | 93% | 92% | 92% | 94% | 93% |
| HepB BD ⁴ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| DTP3 ⁴ | 90% | 90% | 90% | 90% | 89% | 89% | 89% | 88% | 89% | 92% | 93% | 95% | 93% | 92% | 93% | 92% | 92% | 94% | 93% |
| BCG ⁴ | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |


New Zealand: HepB3 vs. DTP



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAg= HepB surface antigen. Data Compiled by APAHV 2019: WHO WPRO Hepatitis B control: country profile 2017¹, World DataBank: World Development Indicators database², Immunization Summary: A statistical reference containing data through 2013³, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates⁴, Global Cancer Observatory: Cancer Today-IARC⁵, Western Pacific Regional Plan for Hepatitis B control through Immunization⁶, National Immunization Data – EPI summaries by country⁷, WPRO TAG meeting 2013⁸

| National Policies on Hepatitis B Screening for Pregnant Women | |
|---|---|
| Mandatory HepB screening in all pregnant women (Y/N) ⁸ | Y |
| -If Y, mandatory reporting of HBs-Ag positive pregnant women to public health department (Y/N) ⁸ | Y |
| HBIG administered with HepB BD to infants born to HBsAg positive women (Y/N) ⁸ | Y |
| - If Y, is it free? (Y/N) | |

| National Policies on Hepatitis B Immunization ⁷ | |
|---|-----------------------|
| Universal newborn HepB immunization (Y/N) ⁷ | Y |
| - If Y, year introduced ⁷ | 1985 |
| -HepB3 nationwide ⁷ | 1988 |
| -Free for all newborns (Y/N) | Y |
| -If free, state year introduced: | |
| Catch-up immunization program for unvaccinated children (Y/N) ⁸ | N |
| - If Y, year introduced | |
| -Free for all unvaccinated children (Y/N) | |
| -If free, state year introduced: | |
| Immunization program for health care workers (Y/N) | Y |
| - If Y, year introduced | |
| -Free for all health care workers(Y/N) | |
| -If free, state year introduced: | |
| HepB newborn immunization included in multiyear plan for EPI (Y/N) ⁸ | Y |
| HepB BD in schedule (Y/N) ⁷ | N |
| Systems to monitor HepB BD ⁷ | None |
| Systems to deliver HepB BD ⁷ | Hospitals, HCs, Homes |
| HepB vaccine funding other than country government (Y/N) | |
| -If Y, please specify funding source: | |



| National Policies on Chronic Hepatitis B Treatment | |
|--|---|
| Treatment for chronic HBV infection covered (Y/N) ⁸ | Y |
| - If Y, year introduced | |
| -Interferon (Y/N) | |
| -Oral antiviral (Y/N) | |

| Certification Status ¹ | |
|--------------------------------------|-----------------|
| Year certification report received | |
| Year certification panel convened | Apr 2012 |
| Year certification approved | Sep 2012 |
| Approved with prevalence <1% or <2%? | <1% in children |